Mankind Pharma: India Business to Recover, BSV Integration on Track. Maintain ADD
Mankind Pharma (Mankind) has witnessed a moderation in its India business in 9MFY25 to single digits (~9% YoY ex-BSV) from mid-double-digit growth...
235 Views
Mankind Pharma - Operationally In-Line; Outshines Industry in Chronic Category
Mankind Pharma (Mankind) delivered in-line operational performance for 3QFY25. The earnings were below estimates due to higher interest outgo on...
214 Views
Pharmaceuticals: IPM: growth recovers to 11.7% in Oct-25
In chronic space, cardiac continues to drive IPM growth in Oct-25 at 17% YoY (+11% in Q2FY26), anti-diabetic at 15% (+9% in Q2FY26), led by...
128 Views
Pharmaceuticals: IPM: grows 6.1% in Sep’25 and 7.2% in Q2FY26
The strong growth in cardiac, respiratory, and oncology was offset by muted growth in anti-infective, gastro, VMN, and pain. For Q2FY26, IPM grew...
217 Views
Pharma and Healthcare (Q2FY26E Results Preview): Q2FY26: Steady sales growth, margin to remain flat
The India Pharma and Healthcare sector is expected to see steady revenue growth but EBITDA margins to remain flatWe project sales/EBITDA growth of...
238 Views